Posts Tagged ‘Keryx’

Keryx’s: Perifosine, Colorectal Cancer Share Price Estimate:

February 2nd, 2010

This analysis focuses on what the share price and market share could be for Keryx’s Perifosine if it performs well in Phase III clinical trials for Colon cancer.

In this analysis I’ll cover the U.S. market only, it is much simpler to gauge the U.S. market share because we have actual statistics that are reliable. According to the American Cancer Society there were 106,100 new cases of colon cancer in the U.S. in 2009. And there were 49,920 deaths as a result of the disease (data here). » Read more: Keryx’s: Perifosine, Colorectal Cancer Share Price Estimate:

4 comments »

Posted in Keryx, Perifosine

Tags:

Keryx’s Share Price Estimate Based Positive Results from the Myeloma Trial

January 29th, 2010

Ok, Pharma Investors. I have put together a brief piece about what I think the share price could possibly hit or not hit based on results from the Phase III trial in Multiple Myeloma.

First thing is first, the Myeloma Trial will be driving the share price regardless » Read more: Keryx’s Share Price Estimate Based Positive Results from the Myeloma Trial

No comments »

Posted in Keryx, Perifosine

Tags:

Keryx’s Perifosine, Slam Dunk Data Leaves Adam F Speechless and With No Comment?

January 25th, 2010

What? No column from Adam F today on the data out of Keryx? That’s odd!

Boy oh boy, did Keryx report some strong results this morning. The company said their lead drug Perifosine performed exceptionally well in a Phase II study of Colon Cancer.
For those that aren’t familiar with the drug or how it works » Read more: Keryx’s Perifosine, Slam Dunk Data Leaves Adam F Speechless and With No Comment?

2 comments »

Posted in Uncategorized

Tags:

Daily Pharma Watch

January 5th, 2010

Alright Pharma Investors, time for the daily pharma watch!!!

Keryx (KERX):

Keryx announced some more positive news this morning about their end-stage renal disease drug Zenerex for people with hyperphosphatemia (in case you are wondering hyperphosphatemia is a condition where » Read more: Daily Pharma Watch

1 comment »

Posted in Uncategorized

Tags:

The Week Ahead

December 27th, 2009

Alright Pharma Investors, I have put together a look ahead as to what kind of news could shape this week.

Vivus (VVUS):

Expect Vivus to file an New Drug Application (NDA) for their Obesity Drug Qnexa this week. The company has stated in many filings that they expect to get the NDA filing in by the end of this year, but have yet to file. Last week competitor Arena Pharmaceuticals beat Vivus to the punch with the NDA filing for their » Read more: The Week Ahead

No comments »

Posted in Uncategorized

Tags:

Keryx Perifosine: Is it the next Multiple Myeloma Wonder Drug?

December 9th, 2009

Alright Keryx fans, today I am going to be doing Part II of Keryx’s Perifosine. If you missed Part I where I go over the drug’s scientific background click here to read it.

Is this drug the next wonder Drug?

I had been holding off on doing the Part II analysis for this drug because I wanted to see what the Overall Survival (OS) data was before I wrote it. Well ladies and gentlemen now we have the data and all I can say is it looks pretty DARN GOOD. So let’s run through the trial’s design and data real quick. » Read more: Keryx Perifosine: Is it the next Multiple Myeloma Wonder Drug?

1 comment »

Posted in Keryx, Perifosine

Tags: